What's in Istituto Ortopedico Rizzoli's pipeline?

Istituto Ortopedico Rizzoli has 9 drugs in our index: 7 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Istituto Ortopedico Rizzoli's portfolio?

Top competitors by shared drug class: Anterogen Co., Ltd., Fundación Santiago Dexeus Font, Hospital for Special Surgery, New York, Instituto Nacional de Traumatologia e Ortopedia, LG Life Sciences.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/istituto-ortopedico-rizzoli.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Istituto Ortopedico Rizzoli — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Istituto Ortopedico Rizzoli pipeline: 7 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Injection of autologous concentrated bone marrow aspirate	Injection of autologous concentrated bone marrow aspirate	marketed
autologous bone marrow concentrate	autologous bone marrow concentrate	marketed
Bone marrow aspirate concentrate injection	Bone marrow aspirate concentrate injection	marketed
ACP	ACP	marketed	Cell therapy / Regenerative medicine product		Orthopedics / Regenerative Medicine
viscosupplementation	viscosupplementation	marketed			Other
injection of hyaluronic acid.	injection of hyaluronic acid.	marketed	Viscosupplement	Joint synovial fluid (viscoelastic properties)	Orthopedics / Rheumatology
bone substitute i-FactorTM	bone substitute i-FactorTM	marketed	Bone graft substitute / Osteoinductive biomaterial	Bone morphogenetic protein signaling pathway	Orthopedics / Bone regeneration
Bone Marrow Concentrate	Bone Marrow Concentrate	phase 3	Autologous stem cell therapy		Orthopedics / Regenerative Medicine

Therapeutic area mix

Orthopedics / Regenerative Medicine · 2
Orthopedics / Bone regeneration · 1
Orthopedics / Rheumatology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Anterogen Co., Ltd. · 1 shared drug class
Fundación Santiago Dexeus Font · 1 shared drug class
Hospital for Special Surgery, New York · 1 shared drug class
Instituto Nacional de Traumatologia e Ortopedia · 1 shared drug class
LG Life Sciences · 1 shared drug class
ProChon Biotech Ltd · 1 shared drug class
Regenexx, LLC · 1 shared drug class
Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Istituto Ortopedico Rizzoli:

Cite this brief

Drug Landscape (2026). Istituto Ortopedico Rizzoli — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/istituto-ortopedico-rizzoli. Accessed 2026-05-17.